Background: Azathioprine (AZA)-induced pancreatitis is an unpredictable and dose-
| INTRODUCTION
Immunosuppressive therapy is integral to the management of inflammatory bowel disease (IBD) including Crohn's disease (CD) and ulcerative colitis (UC). Azathioprine (AZA) is one of several treatments used to manage the dysregulated inflammatory response of IBD. 1, 2 Due to high costs associated with biologics, payers sometimes require patients to be resistant or intolerant to AZA prior to the approval of such agents. Currently, several international societies and federal agencies discourage AZA use as a monotherapy for IBD; however, its use as combination therapy with anti-TNF agents remains a gold standard in high risk IBD patients. [2] [3] [4] [5] AZA is associated with a few, but significant, toxicities that can limit its use in clinical practice. These include nausea, vomiting, myelosuppression, hepatotoxcity or acute pancreatitis. 6 AZA-induced pancreatitis is an idiosyncratic drug reaction that affects 2%-7% of AZA-treated patients with IBD. 6, 7 Risk factors associated with its onset include cigarette smoking and glucocorticoid exposure; however, there are no predictive tests used clinically to identify patients at risk for AZA-induced pancreatitis. 7 Recently, an association between the human leucocyte antigen (HLA) gene region and AZA-induced pancreatitis has been identified. 8 The genome wide association study (GWAS) recognised an association between AZA-induced pancreatitis and the single nucleotide polymorphism (SNP) rs2647087 that maps to the HLA-DQA1*02:01-HLA-DRB1*07:01 haplotype (odds ratio, OR, 2.59).
Heterozygous (A/C) and homozygous (C/C) carriers of the variant allele had 2.5-and 5-fold higher risk of developing AZA-induced pancreatitis respectively compared to those who are homozygous for the common allele (A/A). 8 Given the clinical relevance and potential impact of the findings with regard to the HLA-DQA1*02:01-HLA-DRB1*07:01 haplotype, the aim of our study was to validate the findings in a large and independent cohort of patients with IBD and to further delineate an IBD AZA treatment algorithm based on pharmacogenomic principles.
| MATERIALS AND METHODS

| Subjects
A retrospective cohort study was carried out in 373 individuals with IBD exposed to AZA. Patients taking mercaptopurine (MP) were not included in the final cohort. Subject recruitment took place between July 2012 and March 2017. This cohort was assembled from IBD patients (n = 591) being considered for AZA therapy who were referred to the London Health Sciences Centre Personalized Medicine Service (London, Canada) for thiopurine S-methyltransferase (TPMT) genotyping. Eligible subjects were 18 years of age or older and had a histopathological diagnosis of CD or UC. All subjects were required to have been prescribed AZA by their treating clinician and for their exposure to be documented in their patient chart. Control subjects (no history of AZA-induced pancreatitis) were required to be on AZA for a minimum of 6 months. Subjects diagnosed with AZA-induced pancreatitis were required to meet two of the following three criteria: a minimum elevation in serum lipase three times the upper limit of normal, clinical symptoms of nausea, vomiting and characteristic abdominal pain or radiological evidence of acute pancreatitis. 9 The diagnosis of pancreatitis was made by an independent clinician less than 3 months after exposure to azathioprine in the absence of other causative factors (alcohol, gallstones, other drugs causing pancreatitis, etc.). Severity of acute pancreatitis was classified based on the revised Atlanta criteria. 9 The study protocol was approved by the Western University Health Sciences Research Ethics Board. Data collected on all subjects included IBD diagnosis (CD, UC), age, sex, height, weight, smoking history, disease activity, and AZA response. Additional data specific to AZA-induced pancreatitis cases were collected including dose and duration of AZA exposure preceding the onset of acute pancreatitis, hospitalisation and duration, acute pancreatitis severity, biochemical parameters of pancreatitis, results of abdominal imaging, and concomitant medications.
Subjects were followed up for a minimum of 6 months up to 4 years.
| Genotypic analysis
DNA was extracted from whole blood using a standard DNA extrac- 
| Statistical analysis
Statistical analyses were performed using R statistical software with the "epitools" (Epidemiology Tools) package. 10, 11 Genotype frequencies were compared using a 2 9 3 contingency table with a correction for small sample size and Fisher's exact test; allele frequencies were compared using a 2 9 2 contingency table and Fisher's exact test. Two-sided P-values, odds ratios (OR) and 95% confidence (CI)
were calculated. P-values <.05 were deemed to be statistically significant. Figure 1 highlights patient selection based on the STROBE statement. 12 Three hundred and seventy-three subjects with IBD were exposed to AZA and included in this study (245 CD and 128 UC).
Thirteen subjects were diagnosed with AZA-induced pancreatitis.
Baseline characteristics and demographics are described in Table 1 . Table 2 provides further description on the individuals diagnosed with AZA-induced pancreatitis. The mean time to the onset of acute pancreatitis from the time of first exposure to AZA was 21.9 AE 6.7 days. Subjects were exposed to AZA doses ranging from 50 mg to 300 mg, with a mean dose of 128.85 AE 90.05 mg. All cases of acute pancreatitis were mild based on the revised Atlanta criteria. 9 with no associated complications. All subjects required admission to hospital. The mean length of stay was 2 AE 1.63 days.
All subjects underwent genotyping for the class II HLA gene region at rs2647087. The genotype and minor allele frequencies classified by the presence or absence of acute pancreatitis are displayed in Table 3 . Across the entire cohort, the HLA rs2647087 Available for HLA genotyping n = 360 
| DISCUSSION
The use of AZA for the treatment of CD and UC has been well-documented over the last 4 decades. Drug-induced acute pancreatitis is an unfortunate, unpredictable and dose-independent complication that can arise with AZA exposure. The prevalence of AZA-induced acute pancreatitis in our IBD population (3.49%) aligns with the 2%-7% rate reported in the literature. 6 ,7 Pancreatitis appears to be mild in these individuals, without evidence of organ failure or lasting complication.
Our findings confirm an important role of the class II HLA gene region at rs2647087 as demonstrated in the GWAS by Heap et al. 8 However, we note that those who are wild-type (A/A) for the rs2647087 SNP appear to have a much lower than average risk for pancreatitis (0.54%). The study by Heap et al noted a 2.5-and fivefold higher risk of pancreatitis for those who are rs2647087 A/C or C/C compared to those who are A/A. 8 Our finding suggests the pancreatitis risk is in fact much higher, 4-and 15-fold for rs2647087 A/ C and C/C patients respectively. Although patients on MP were not directly assessed in this study, azathioprine is a prodrug of MP. In the study by Heap et al patients on either azathioprine or MP had been enrolled and there was no indication that being on either medication alters the risk for pancreatitis. 8 Heap et al 8 allele as a companion diagnostic test before being initiated on therapy. 17 Although caution must be taken when interpreting these results given the small number of cases, this study highlights the potential utility of prospectively screening IBD patients being considered for AZA therapy for the rs2647087genotype given its predictive effect and the fact that other, potentially more efficacious, treatments are available for patients deemed to be higher risk for AZA-induced pancreatitis.
Accordingly, we propose a genotype-guided algorithm for the treatment of patients with IBD with AZA, which takes into account TPMT genotype as well as the class II HLA rs2647087 genotype % of patients P a n c r e a t i t i s N o p a n c r e a t i t i s n = 13 n = 360 A/C A/A C/C F I G U R E 2 Genotype frequency stratified by pancreatitis diagnosis. Genotypes are expressed as a percentage of the total population of the pancreatitis cases (n = 13) and controls (n = 360). Number, n Currently, payers across many jurisdictions require that patients try and fail low cost immunomodulators, such as AZA, prior to the initiation of more effective and costly biological therapies. 18 It should be noted that treatment of AZA-induced pancreatitis results in added health care costs. Hospitalisation costs alone relating to acute pancreatitis can be over $10,000 (US) per individual, depending on the length of stay and investigations pursued. 19, 20 In summary, class II HLA gene region at rs2647087 appears to be an important marker of AZA-induced pancreatitis risk, though caution must be taken due to the small number pancreatitis cases identified in this study. The marked increase in risk for pancreatitis among carriers of the variant allele provides a strong rationale for a companion diagnostic approach for patients who are to be pre- 
